



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/445,289	05/11/2000	GALINA V MUKAMOLOVA	49946-60261	9774

7590 08/20/2007
EDWARDS ANGELL PALMER & DODGE LLP
P.O. BOX 55874
BOSTON, MA 02205

EXAMINER

DEVI, SARVAMANGALA J N

ART UNIT	PAPER NUMBER
----------	--------------

1645

MAIL DATE	DELIVERY MODE
-----------	---------------

08/20/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/445,289	05/11/00	Mukamolova et al.	49946-60261

EXAMINER	
S. Devi, Ph.D.	
ART UNIT	PAPER NUMBER
1645	082007

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

The communication filed 08/01/07 is not fully responsive to the Office communication mailed 02/01/07 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules and/or CRF Diskette Problem Report. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.


Since the above-mentioned reply appears to be a *bona fide* attempt to comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825), Applicant is given a TIME PERIOD of **ONE (1) MONTH** from the mailing date of this communication within which to correct the deficiency so as to comply with the sequence rules (37 CFR 1.821 - 1.825) in order to avoid abandonment of the application under 37 CFR 1.821(g). EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to S. Devi, Ph.D., whose telephone number is (571) 272-0854. A message may be left on the Examiner's voice mail system. The Examiner can normally be reached on Monday-Friday from 7:15 a.m. to 4:15 p.m. (Eastern Time) except one day each bi-week, which would be disclosed on the Examiner's voice mail system.

If attempts to reach the Examiner by telephone are unsuccessful, her supervisor, Jeffrey Siew, can be reached at (571) 272-0787. The FAX phone number for group 1645 is (571) 273-8300.

An inquiry of a general nature or relating to the status of the application should be directed to the group receptionist whose telephone number is (571) 272-1600.

August, 2007


S. DEVI, PH.D.
PRIMARY EXAMINER

Notice to Comply	Application No. 09445289	Applicant(s) Mukamalova et al.	
	Examiner S.Devi, Ph.D.	Art Unit 1645	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 or (703) 308-2923

For CRF Submission Help, call (703) 308-4212 or 308-2923

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

=====

Sequence Listing could not be accepted due to errors.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: Tue Aug 14 09:28:38 EDT 2007

=====

Reviewer Comments:

<210> 11

<211> 320

<212> PRT

<213> Clostridium acetobutylicum

<220>

<221> MOD_RES

<222> (2)..(3)

<223> Variable amino acid

<400> 11

Lys	Arg	Xaa	Xaa	Ala	Val	Ile	Leu	Met	Val	Ala	Val	Ile	Phe	Thr	Ile
1				5				10				15			

The above <222> response is incorrect: the Xaa's are at locations 3 and 4.

Application No: 09445289

Version No: 8.0

Input Set:

Output Set:

Started: 2007-08-13 16:20:28.993

Finished: 2007-08-13 16:20:30.790

Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 797 ms

Total Warnings: 12

Total Errors: 8

No. of SeqIDs Defined: 63

Actual SeqID Count: 63

Error code	Error Description
E 257	Invalid sequence data feature in <221> in SEQ ID (11)
E 341	'Xaa' position not defined SEQID (11) POS (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (37)
E 257	Invalid sequence data feature in <221> in SEQ ID (38)
E 257	Invalid sequence data feature in <221> in SEQ ID (38)
W 213	Artificial or Unknown found in <213> in SEQ ID (39)
W 213	Artificial or Unknown found in <213> in SEQ ID (40)
W 213	Artificial or Unknown found in <213> in SEQ ID (41)
W 213	Artificial or Unknown found in <213> in SEQ ID (46)
W 213	Artificial or Unknown found in <213> in SEQ ID (47)
W 213	Artificial or Unknown found in <213> in SEQ ID (48)
W 213	Artificial or Unknown found in <213> in SEQ ID (49)
W 213	Artificial or Unknown found in <213> in SEQ ID (50)
W 213	Artificial or Unknown found in <213> in SEQ ID (51)
W 213	Artificial or Unknown found in <213> in SEQ ID (52)
W 213	Artificial or Unknown found in <213> in SEQ ID (53)
E 257	Invalid sequence data feature in <221> in SEQ ID (60)
E 257	Invalid sequence data feature in <221> in SEQ ID (61)
E 257	Invalid sequence data feature in <221> in SEQ ID (61)
E 257	Invalid sequence data feature in <221> in SEQ ID (62)

SEQUENCE LISTING

<110> MUKAMOLOVA, GALINA V.
 KAPRELYANTS, ARSENY S.
 YOUNG, DANIELLE I.
 KELL, DOUGLAS B.
 YOUNG, MICHAEL

<120> BACTERIAL PHEROMONES AND USES THEREFOR

<130> 49946-60261

<140> 09445289

<141> 2000-05-11

<150> 09/445,289

<151> 2000-05-11

<150> PCT/GB98/01619

<151> 1998-06-03

<150> GB 9711389.8

<151> 1997-06-04

<150> GB 9811221.2

<151> 1998-05-27

<160> 63

<170> PatentIn Ver. 3.3

<210> 1

<211> 362

<212> PRT

<213> Mycobacterium tuberculosis

<400> 1

Met Leu Arg Leu Val Val Gly Ala Leu Leu Leu Val Leu Ala Phe Ala
 1 5 10 15

Gly Gly Tyr Ala Val Ala Ala Cys Lys Thr Val Thr Leu Thr Val Asp
 20 25 30

Gly Thr Ala Met Arg Val Thr Thr Met Lys Ser Arg Val Ile Asp Ile
 35 40 45

Val Glu Glu Asn Gly Phe Ser Val Asp Asp Arg Asp Asp Leu Tyr Pro
 50 55 60

Ala Ala Gly Val Gln Val His Asp Ala Asp Thr Ile Val Leu Arg Arg
 65 70 75 80

Ser Arg Pro Leu Gln Ile Ser Leu Asp Gly His Asp Ala Lys Gln Val
 85 90 95

Trp Thr Thr Ala Ser Thr Val Asp Glu Ala Leu Ala Gln Leu Ala Met
 100 105 110

Thr Asp Thr Ala Pro Ala Ala Ala Ser Arg Ala Ser Arg Val Pro Leu
 115 120 125
 Ser Gly Met Ala Leu Pro Val Val Ser Ala Lys Thr Val Gln Leu Asn
 130 135 140
 Asp Gly Gly Leu Val Arg Thr Val His Leu Pro Ala Pro Asn Val Ala
 145 150 155 160
 Gly Leu Leu Ser Ala Ala Gly Val Pro Leu Leu Gln Ser Asp His Val
 165 170 175
 Val Pro Ala Ala Thr Ala Pro Ile Val Glu Gly Met Gln Ile Gln Val
 180 185 190
 Thr Arg Asn Arg Ile Lys Lys Val Thr Glu Arg Leu Pro Leu Pro Pro
 195 200 205
 Asn Ala Arg Arg Val Glu Asp Pro Glu Met Asn Met Ser Arg Glu Val
 210 215 220
 Val Glu Asp Pro Gly Val Pro Gly Thr Gln Asp Val Thr Phe Ala Val
 225 230 235 240
 Ala Glu Val Asn Gly Val Glu Thr Gly Arg Leu Pro Val Ala Asn Val
 245 250 255
 Val Val Thr Pro Ala His Glu Ala Val Val Arg Val Gly Thr Lys Pro
 260 265 270
 Gly Thr Glu Val Pro Pro Val Ile Asp Gly Ser Ile Trp Asp Ala Ile
 275 280 285
 Ala Gly Cys Glu Ala Gly Gly Asn Trp Ala Ile Asn Thr Gly Asn Gly
 290 295 300
 Tyr Tyr Gly Gly Val Gln Phe Asp Gln Gly Thr Trp Glu Ala Asn Gly
 305 310 315 320
 Gly Leu Arg Tyr Ala Pro Arg Ala Asp Leu Ala Thr Arg Glu Glu Gln
 325 330 335
 Ile Ala Val Ala Glu Val Thr Arg Leu Arg Gln Gly Trp Gly Ala Trp
 340 345 350
 Pro Val Cys Ala Ala Arg Ala Gly Ala Arg
 355 360

<210> 2

<211> 188

<212> PRT

<213> Mycobacterium tuberculosis

<400> 2

Met Pro Val Gly Trp Leu Trp Arg Ala Arg Thr Ala Lys Gly Thr Thr

1	5	10	15
Leu Lys Asn Ala Arg Thr Thr Leu Ile Ala Ala Ala Ile Ala Gly Thr			
20	25	30	
Leu Val Thr Thr Ser Pro Ala Gly Ile Ala Asn Ala Asp Asp Ala Gly			
35	40	45	
Leu Asp Pro Asn Ala Ala Ala Gly Pro Asp Ala Val Gly Phe Asp Pro			
50	55	60	
Asn Leu Pro Pro Ala Pro Asp Ala Ala Pro Val Asp Thr Pro Pro Ala			
65	70	75	80
Pro Glu Asp Ala Gly Phe Asp Pro Asn Leu Pro Pro Pro Leu Ala Pro			
85	90	95	
Asp Phe Leu Ser Pro Pro Ala Glu Glu Ala Pro Pro Val Pro Val Ala			
100	105	110	
Tyr Ser Val Asn Trp Asp Ala Ile Ala Gln Cys Glu Ser Gly Gly Asn			
115	120	125	
Trp Ser Ile Asn Thr Gly Asn Gly Tyr Tyr Gly Gly Leu Arg Phe Thr			
130	135	140	
Ala Gly Thr Trp Arg Ala Asn Gly Gly Ser Gly Ser Ala Ala Asn Ala			
145	150	155	160
Ser Arg Glu Glu Gln Ile Arg Val Ala Glu Asn Val Leu Arg Ser Gln			
165	170	175	
Gly Ile Arg Ala Trp Pro Val Cys Gly Arg Arg Gly			
180	185		

<210> 3

<211> 174

<212> PRT

<213> Mycobacterium leprae

<400> 3

Met Ser Glu Ser Tyr Arg Lys Leu Thr Thr Ser Ser Ile Ile Val Ala			
1	5	10	15
Lys Ile Thr Phe Thr Gly Ala Met Leu Asp Gly Ser Ile Ala Leu Ala			
20	25	30	
Gly Gln Ala Ser Pro Ala Thr Asp Ser Glu Trp Asp Gln Val Ala Arg			
35	40	45	
Cys Glu Ser Gly Gly Asn Trp Ser Ile Asn Thr Gly Asn Gly Tyr Leu			
50	55	60	
Gly Gly Leu Gln Phe Ser Gln Gly Thr Trp Ala Ser His Gly Gly Gly			
65	70	75	80

Glu Tyr Ala Pro Ser Ala Gln Leu Ala Thr Arg Glu Gln Gln Ile Ala
85 90 95

Val Ala Glu Arg Val Leu Ala Thr Gln Gly Ser Gly Ala Trp Pro Ala
100 105 110

Cys Gly His Gly Leu Ser Gly Pro Ser Leu Gln Glu Val Leu Pro Ala
115 120 125

Gly Met Gly Ala Pro Trp Ile Asn Gly Ala Pro Ala Pro Leu Ala Pro
130 135 140

Pro Pro Pro Ala Glu Pro Ala Pro Pro Gln Pro Pro Ala Asp Asn Phe
145 150 155 160

Pro Pro Thr Pro Gly Asp Val Pro Ser Pro Leu Ala Arg Pro
165 170

<210> 4

<211> 407

<212> PRT

<213> Mycobacterium tuberculosis

<400> 4

Met Ser Gly Arg His Arg Lys Pro Thr Thr Ser Asn Val Ser Val Ala
1 5 10 15

Lys Ile Ala Phe Thr Gly Ala Val Leu Gly Gly Gly Gly Ile Ala Met
20 25 30

Ala Ala Gln Ala Thr Ala Ala Thr Asp Gly Glu Trp Asp Gln Val Ala
35 40 45

Arg Cys Glu Ser Gly Gly Asn Trp Ser Ile Asn Thr Gly Asn Gly Tyr
50 55 60

Leu Gly Gly Leu Gln Phe Thr Gln Ser Thr Trp Ala Ala His Gly Gly
65 70 75 80

Gly Glu Phe Ala Pro Ser Ala Gln Leu Ala Ser Arg Glu Gln Gln Ile
85 90 95

Ala Val Gly Glu Arg Val Leu Ala Thr Gln Gly Arg Gly Ala Trp Pro
100 105 110

Val Cys Gly Arg Gly Leu Ser Asn Ala Thr Pro Arg Glu Val Leu Pro
115 120 125

Ala Ser Ala Ala Met Asp Ala Pro Leu Asp Ala Ala Val Asn Gly
130 135 140

Glu Pro Ala Pro Leu Ala Pro Pro Pro Ala Asp Pro Ala Pro Pro Val
145 150 155 160

Glu Leu Ala Ala Asn Asp Leu Pro Ala Pro Leu Gly Glu Pro Leu Pro
165 170 175

Ala Ala Pro Ala Asp Pro Ala Pro Pro Ala Asp Leu Ala Pro Pro Ala
 180 185 190
 Pro Ala Asp Val Ala Pro Pro Val Glu Leu Ala Val Asn Asp Leu Pro
 195 200 205
 Ala Pro Leu Gly Glu Pro Leu Pro Ala Ala Pro Ala Asp Pro Ala Pro
 210 215 220
 Pro Ala Asp Leu Ala Pro Pro Ala Pro Ala Asp Leu Ala Pro Pro Ala
 225 230 235 240
 Pro Ala Asp Leu Ala Pro Pro Ala Pro Ala Asp Leu Ala Pro Pro Val
 245 250 255
 Glu Leu Ala Val Asn Asp Leu Pro Ala Pro Leu Gly Glu Pro Leu Pro
 260 265 270
 Ala Ala Pro Ala Glu Leu Ala Pro Pro Ala Asp Leu Ala Pro Ala Ser
 275 280 285
 Ala Asp Leu Ala Pro Pro Ala Pro Ala Asp Leu Ala Pro Pro Ala Pro
 290 295 300
 Ala Glu Leu Ala Pro Pro Ala Pro Ala Asp Leu Ala Pro Pro Ala Ala
 305 310 315 320
 Val Asn Glu Gln Thr Ala Pro Gly Asp Gln Pro Ala Thr Ala Pro Gly
 325 330 335
 Gly Pro Val Gly Leu Ala Thr Asp Leu Glu Leu Pro Glu Pro Asp Pro
 340 345 350
 Gln Pro Ala Asp Ala Pro Pro Pro Gly Asp Val Thr Glu Ala Pro Ala
 355 360 365
 Glu Thr Pro Gln Val Ser Asn Ile Ala Tyr Thr Lys Lys Leu Trp Gln
 370 375 380
 Ala Ile Arg Ala Gln Asp Val Cys Gly Asn Asp Ala Leu Asp Ser Leu
 385 390 395 400
 Ala Gln Pro Tyr Val Ile Gly
 405

<210> 5

<211> 155

<212> PRT

<213> *Mycobacterium leprae*

<400> 5

Met Pro Gly Glu Met Leu Asp Val Arg Lys Leu Cys Lys Leu Phe Val
 1 5 10 15

Lys Ser Ala Val Val Ser Gly Ile Val Thr Ala Ser Met Ala Leu Ser

20

25

30

Thr Ser Thr Gly Met Ala Asn Ala Val Pro Arg Glu Pro Asn Trp Asp

35

40

45

Ala Val Ala Gln Cys Glu Ser Gly Arg Asn Trp Arg Ala Asn Thr Gly

50

55

60

Asn Gly Phe Tyr Gly Gly Leu Gln Phe Lys Pro Thr Ile Trp Ala Arg

65

70

75

80

Tyr Gly Gly Val Gly Asn Pro Ala Gly Ala Ser Arg Glu Gln Gln Ile

85

90

95

Thr Val Ala Asn Arg Val Leu Ala Asp Gln Gly Leu Asp Ala Trp Pro

100

105

110

Lys Cys Gly Ala Ala Ser Asp Leu Pro Ile Thr Leu Trp Ser His Pro

115

120

125

Ala Gln Gly Val Lys Gln Ile Ile Asn Asp Ile Ile Gln Met Gly Asp

130

135

140

Thr Thr Leu Ala Ala Ile Ala Leu Asn Gly Leu

145

150

155

<210> 6

<211> 176

<212> PRT

<213> Mycobacterium tuberculosis

<400> 6

Met His Pro Leu Pro Ala Asp His Gly Arg Ser Arg Cys Asn Arg His

1

5

10

15

Pro Ile Ser Pro Leu Ser Leu Ile Gly Asn Ile Ser Ala Thr Ser Gly

20

25

30

Asp Met Ser Ser Met Thr Arg Ile Ala Lys Pro Leu Ile Lys Ser Ala

35

40

45

Met Ala Ala Gly Leu Val Thr Ala Ser Met Ser Leu Ser Thr Ala Val

50

55

60

Ala His Ala Gly Pro Ser Pro Asn Trp Asp Ala Val Ala Gln Cys Glu

65

70

75

80

Ser Gly Gly Asn Trp Ala Ala Asn Thr Gly Asn Gly Lys Tyr Gly Gly

85

90

95

Leu Gln Phe Lys Pro Ala Thr Trp Ala Ala Phe Gly Gly Val Gly Asn

100

105

110

Pro Ala Ala Ala Ser Arg Glu Gln Gln Ile Ala Val Ala Asn Arg Val

115

120

125

Leu Ala Glu Gln Gly Leu Asp Ala Trp Pro Thr Cys Gly Ala Ala Ser
130 135 140

Gly Leu Pro Ile Ala Leu Trp Ser Lys Pro Ala Gln Gly Ile Lys Gln
145 150 155 160

Ile Ile Asn Glu Ile Ile Trp Ala Gly Ile Gln Ala Ser Ile Pro Arg
165 170 175

<210> 7

<211> 154

<212> PRT

<213> Mycobacterium tuberculosis

<400> 7

Met Thr Pro Gly Leu Leu Thr Thr Ala Gly Ala Gly Arg Pro Arg Asp
1 5 10 15

Arg Cys Ala Arg Ile Val Cys Thr Val Phe Ile Glu Thr Ala Val Val
20 25 30

Ala Thr Met Phe Val Ala Leu Leu Gly Leu Ser Thr Ile Ser Ser Lys
35 40 45

Ala Asp Asp Ile Asp Trp Asp Ala Ile Ala Gln Cys Glu Ser Gly Gly
50 55 60

Asn Trp Ala Ala Asn Thr Gly Asn Gly Leu Tyr Gly Gly Leu Gln Ile
65 70 75 80

Ser Gln Ala Thr Trp Asp Ser Asn Gly Gly Val Gly Ser Pro Ala Ala
85 90 95

Ala Ser Pro Gln Gln Gln Ile Glu Val Ala Asp Asn Ile Met Lys Thr
100 105 110

Gln Gly Pro Gly Ala Trp Pro Lys Cys Ser Ser Cys Ser Gln Gly Asp
115 120 125

Ala Pro Leu Gly Ser Leu Thr His Ile Leu Thr Phe Leu Ala Ala Glu
130 135 140

Thr Gly Gly Cys Ser Gly Ser Arg Asp Asp
145 150

<210> 8

<211> 99

<212> PRT

<213> Streptomyces coelicolor

<400> 8

Ile Arg Thr Ala Ala Val Thr Leu Val Ala Ala Thr Ala Leu Gly Ala

1	5	10	15
Thr Gly Glu Ala Val Ala Ala Pro Ser Ala Pro Leu Arg Thr Asp Trp			
20	25	30	
Asp Ala Ile Ala Ala Cys Glu Ser Ser Gly Asn Trp Gln Ala Asn Thr			
35	40	45	
Gly Asn Gly Tyr Tyr Gly Gly Leu Gln Phe Ala Arg Ser Ser Trp Ile			
50	55	60	
Ala Ala Gly Gly Leu Lys Tyr Ala Pro Arg Ala Asp Leu Ala Thr Arg			
65	70	75	80
Gly Glu Gln Ile Ala Val Ala Glu Arg Leu Ala Arg Leu Gln Gly Met			
85	90	95	
Ser Ala Trp			

<210> 9
 <211> 438
 <212> PRT
 <213> Bacillus subtilis

<400> 9
Met Gly Glu Arg Glu Gly Arg Val Asp Ser Leu Leu Asp Thr Leu Tyr
1 5 10 15
Asn Leu Ser Glu Glu Lys Glu Ala Phe Phe Ile Thr Gln Lys Met Lys
20 25 30
Lys Leu Phe Ser Val Lys Leu Ser Lys Ser Lys Val Ile Leu Val Ala
35 40 45
Ala Cys Leu Leu Leu Ala Gly Ser Gly Thr Ala Tyr Ala Ala His Glu
50 55 60
Leu Thr Lys Gln Ser Val Ser Val Ser Ile Asn Gly Lys Lys Lys His
65 70 75 80
Ile Arg Thr His Ala Asn Thr Val Gly Asp Leu Leu Glu Thr Leu Asp
85 90 95
Ile Lys Thr Arg Asp Glu Asp Lys Ile Thr Pro Ala Lys Gln Thr Lys
100 105 110
Ile Thr Ala Asp Met Asp Val Val Tyr Glu Ala Ala Lys Pro Val Lys
115 120 125
Leu Thr Ile Asn Gly Glu Glu Lys Thr Leu Trp Ser Thr Ala Lys Thr
130 135 140
Val Gly Ala Leu Leu Asp Glu Gln Asp Val Asp Val Lys Glu Gln Asp
145 150 155 160

Gln Ile Asp Pro Ala Ile Asp Thr Asp Ile Ser Lys Asp Met Lys Ile
165 170 175

Asn Ile Glu Pro Ala Phe Gln Val Thr Val Asn Asp Ala Gly Lys Gln
180 185 190

Lys Lys Ile Trp Thr Thr Ser Thr Thr Val Ala Asp Phe Leu Lys Gln
195 200 205

Gln Lys Met Asn Ile Lys Asp Glu Asp Lys Ile Lys Pro Ala Leu Asp
210 215 220

Ala Lys Leu Thr Lys Gly Lys Ala Asp Ile Thr Ile Thr Arg Ile Glu
225 230 235 240

Lys Val Thr Asp Val Val Glu Glu Lys Ile Ala Phe Asp Val Lys Lys
245